ALCHEMIA LAUNCHES INTO INDIA

Written on the 4 June 2013

ALCHEMIA LAUNCHES INTO INDIA

BRISBANE drug development company Alchemia Limited (ASX: ACL) has launched a deep vein thrombosis prevention drug into India following success in the United States.

Fondaparinux is an injectable coagulant approved in the United States for the prevention and treatment of deep vein thrombosis after knee or hip surgery. It will be sold and marketed in India by international marketing partner Dr Reddy’s Laboratories Inc. under the name Fondared.

The drug is a generic version of GlaxoSmithKline’s Arixtra which achieved Indian sales of around $US2.7 million during the 2012 calendar year.

ACL expects to receive 25% of all profits from sales in India with the same economies from sales from any further territories outside the United States.

Dr Reddy’s Laboratories has filed a regulatory submission in Europe seeking marketing approval for the drug in key European markets.

CEO Charles Walker says the launch represents a milestone for the company.

“This launch represents the first for our fondaparinux outside of the U.S.,” he says.

“We look forward to fondaparinux’s expansion into additional territories.”

Meanwhile ACL’s pipeline of oncology products continues to develop.

The company recently announced the final recruitment of 390 patients for its most advanced cancer drug, HA-Irinotecan, which is in Phase III for the treatment of metastatic colorectal cancer.

The treatments are built on targeted cancer delivery which is used to selectively target cancer drugs to tumours.


Latest News

SLATER AND GORDON TAKES SPOTLESS TO COURT

SPOTLESS Group (ASX: SPO) has been hit by a class action launched by Slater and Gordon (ASX: SGH) in the Federal C...

ANSELL'S SHARE PRICE SWELLS AFTER SALE OF CONDOM BUSINESS

IT'S one of Australia's most successful and enduring manufacturing success stories and the Ansell condom busi...

TOPSHOP GOES INTO ADMINISTRATION AMID VOLATILE RETAIL MARKET

TOPSHOP has become the latest in a string of retailers blasted by the volatile retail market, as the iconic fashio...

SIGMA'S SHARE PRICE TAKES A BATTERING AS IT LAUNCHES LEGAL ACTION OVER SUPPLY DEAL

SIGMA Healthcare (ASX: SIG) has taken the MyChemist and Chemist Warehouse chains to court to demand they continue to ...

Related News

SLATER AND GORDON TAKES SPOTLESS TO COURT

SPOTLESS Group (ASX: SPO) has been hit by a class action launched by Slater and Gordon (ASX: SGH) in the Federal C...

TOPSHOP GOES INTO ADMINISTRATION AMID VOLATILE RETAIL MARKET

TOPSHOP has become the latest in a string of retailers blasted by the volatile retail market, as the iconic fashio...

SIGMA'S SHARE PRICE TAKES A BATTERING AS IT LAUNCHES LEGAL ACTION OVER SUPPLY DEAL

SIGMA Healthcare (ASX: SIG) has taken the MyChemist and Chemist Warehouse chains to court to demand they continue to ...

REGIONAL BANKS HIT OUT AT RATING CUT AND WARN BIG FOUR WILL BENEFIT

REGIONAL banks have hit out at a downgrade on their credit ratings, warning that it will increase their wholesale fun...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter